SARTORIUS STEDIM BIOTECH


Associated tags: Security (finance), Regulatory News Service, Broadcasting

Locations: FRANCE, ASIA, NORTH AMERICA, EUROPE, PARIS, FRANKREICH, EUROPEAN UNION, UNITED KINGDOM, AUSTRALIA, GERMANY, UNITED STATES, JAPAN, SOUTH AFRICA, EU, CANADA

Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Retrieved on: 
Friday, February 16, 2024
Sartorius AG, Disclosure, BOARD, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The person making the disclosure is a closely associated person mentioned of article 3.26) of Regulation (EU) No 596/2014 of April 16, 2014 on market abuse.
  • Please give the identity and functions of the person with whom the reporting person has close personal ties.
  • Position / status: Sartorius AG legal entity related to JOACHIM KREUZBURG, CHAIRMAN OF THE BOARD and RENE FABER, CEO
    This notification is an initial notification.

Sartorius Stedim Biotech: Information on Document Availability

Retrieved on: 
Friday, February 16, 2024
Sartorius AG, Bank statement, Euronext, Euronext Paris

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Sartorius Stedim Biotech Group’s Universal Registration Document 2023 is now available at:
    It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2023
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights

Retrieved on: 
Wednesday, February 7, 2024
Financial services, Failure, Order, Person, European, Prospectus, European Economic Area, Council, Gross metropolitan product, Advertising, Risk, State, Sale, AMF, European Parliament, Equity carve-out, Finance, Security (finance)

This press release may not be published, distributed or released in South Africa, Australia, Canada or Japan.

Key Points: 
  • This press release may not be published, distributed or released in South Africa, Australia, Canada or Japan.
  • The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations.
  • Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
  • This announcement may not be published, forwarded or distributed, directly or indirectly, in South Africa, Australia, Canada or Japan.

Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding

Retrieved on: 
Tuesday, February 6, 2024
Financial services, Failure, Sartorius AG, Order, Person, European, Prospectus, European Economic Area, Council, Gross metropolitan product, Advertising, Risk, State, Sale, AMF, European Parliament, Equity carve-out, Finance, Security (finance)

This press release may not be published, distributed or released in South Africa, Australia, Canada or Japan.

Key Points: 
  • This press release may not be published, distributed or released in South Africa, Australia, Canada or Japan.
  • The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations.
  • The issuance by the Issuer or the subscription of the Shares may be subject to legal and regulatory restrictions in certain jurisdictions.
  • This announcement may not be published, forwarded or distributed, directly or indirectly, in South Africa, Australia, Canada or Japan.